Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

hat we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2007 Annual Information Form filed on SEDAR at http://www.sedar.com. Historical filings relating to the Company prior to the completion of the Company's March 23, 2006 corporate reorganization may be reviewed on SEDAR at http://www.sedar.com under the SEDAR profile GVIC Communications Corp.

All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Nventa Biopharmaceuticals Corp

Condensed Consolidated Statement of Operations

(Unaudited)

(Canadian dollars)(In thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Revenue:

Collaborative research

and development revenue $156 $156 $621 $621

Operating expenses:

Research and development 1,549 1,587 6,596 7,351

Selling, general and

administrative 922 714 4,529 3,565

Corporate restructuring 30 - 844 -

2,501 2,301 11,969 1
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... Willow Grove, PA (PRWEB) August 28, 2014 ... talent, and create a culture that will allow individuals ... that are becoming increasingly important for employers looking to ... life science industries are embracing this trend, as the ... the fabric of a company, which will have real ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... Genzyme Products, CAMBRIDGE, Mass., Sept. 18 Genzyme ... significant expansion of its,flagship manufacturing facility at Allston Landing ... space for manufacturing support,functions, and will allow for the ... by a ceremony featuring Massachusetts Governor,Deval L. Patrick, Boston ...
... - the New ISI Web of Knowledge - to ... Throughout the Country, PHILADELPHIA and LONDON, Sept. 18 ... TOC ; TSX: TOC) and,leading provider of information solutions ... Spain,s La Fundacion Espanola,para la Ciencia y la Tecnologia ...
... GSK Increases Research Effort to Target Drug-Resistant Gram Negative ... ... GlaxoSmithKline (NYSE:,GSK) today announced that it has signed an agreement ... Defense (DOD), to,identify and develop a new class of antibacterials targeting ...
Cached Biology Technology:Genzyme Begins Major Expansion of Boston Manufacturing Facility 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 3Genzyme Begins Major Expansion of Boston Manufacturing Facility 4Genzyme Begins Major Expansion of Boston Manufacturing Facility 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program 2GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program 3
(Date:8/28/2014)... (ESA) is pleased to announce the selection of Dr. ... Honorary Membership acknowledges those who have served ESA for ... affairs of the Society that has reached an extraordinary ... ESA Governing Board and then voted on by the ... Awards Ceremony at Entomology 2014, ESA,s Annual Meeting in ...
(Date:8/28/2014)... expansion of marine protected areas is needed to protect ... to investigators from the Wildlife Conservation Society and other ... saving the largest numbers of species, often at the ... ecological functions. , Many vital ecological functions ... also are food for millions of people. This ...
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2Second-hand e-cig smoke compared to regular cigarette smoke 2
... Miami Beach, FL (March 5, 2010) Research presented ... Annual Meeting of the American Academy of Dermatology (Miami ... multiple perspectives, offering insights into how ingredient formulations, care ... are on display, discussing a wide range of topics, ...
... Genetics Society of America is pleased to announce the ... 1, 2010, at the University of British Columbia (UBC) ... investigators studying various aspects of eukaryotic biology in yeast. ... and a Canadian astronaut who is also a Member ...
... discovered a key reason why a form of leukemia ... phase called blast crisis. The study, led by cancer ... G. James Cancer Hospital and Richard J. Solove Research ... when immature white blood cells lose a molecule called ...
Cached Biology News:P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 3P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 42010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Study identifies key cause of chronic leukemia progression 2
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Request Info...
Biology Products: